BMB Reports最新文献_第10页

Gefitinib induces anoikis in cervical cancer cells. 吉非替尼能诱导宫颈癌细胞发生厌氧反应。

IF 3.8 3区生物学

BMB Reports Pub Date : 2024-02-01

Byung Chul Jung, Sung-Hun Woo, Sung Hoon Kim, Yoon Suk Kim

{"title":"Gefitinib induces anoikis in cervical cancer cells.","authors":"Byung Chul Jung, Sung-Hun Woo, Sung Hoon Kim, Yoon Suk Kim","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Gefitinib exerts anticancer effects on various types of cancer, such as lung, ovarian, breast, and colon cancers. However, the therapeutic effects of gefitinib on cervical cancer and the underlying mechanisms remain unclear. Thus, this study aimed to explore whether gefitinib can be used to treat cervical cancer and elucidate the underlying mechanisms. Results showed that gefitinib induced a caspase-dependent apoptosis of HeLa cells, which consequently became round and detached from the surface of the culture plate. Gefitinib induced the reorganization of actin cytoskeleton and downregulated the expression of p-FAK, integrin β1 and E-cadherin, which are important in cell-extracellular matrix adhesion and cell-cell interaction, respectively. Moreover, gefitinib hindered cell reattachment and spreading and suppressed interactions between detached cells in suspension, leading to poly (ADP-ribose) polymerase cleavage, a hallmark of apoptosis. It also induced detachment-induced apoptosis (anoikis) in C33A cells, another cervical cancer cell line. Taken together, these results suggest that gefitinib triggers anoikis in cervical cancer cells. Our findings may serve as a basis for broadening the range of anticancer drugs used to treat cervical cancer. [BMB Reports 2024; 57(2): 104-109].</p>","PeriodicalId":9010,"journal":{"name":"BMB Reports","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10910092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139671150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic potential of BMSC-conditioned medium in an in vitro model of renal fibrosis using the RPTEC/TERT1 cell line 在使用 RPTEC/TERT1 细胞系的肾纤维化体外模型中，BMSC 调节培养基的治疗潜力

IF 3.8 3区生物学

BMB Reports Pub Date : 2024-01-31 DOI: 10.5483/BMBRep.2023-0239

Yunji Kim, D. Kang, Ga-Eun Choi, Sang Dae Kim, Sun-Ja Yang, Hyosang Kim, D. You, Choung Soo Kim, N. Suh

引用次数: 0

Gefitinib induces anoikis in cervical cancer cells 吉非替尼诱导宫颈癌细胞发生厌氧反应

IF 3.8 3区生物学

BMB Reports Pub Date : 2024-01-26 DOI: 10.5483/bmbrep.2023-0225

Byung Chul Jung, Sung-Hun Woo, Sung Hoon Kim, Y. Kim

引用次数: 0

Phenotypic characterization of pre-harvest sprouting resistance mutants generated by the CRISPR/Cas9-geminiviral replicon system in rice 通过 CRISPR/Cas9 基因病毒复制子系统生成的水稻收获前发芽抗性突变体的表型特征

IF 3.8 3区生物学

BMB Reports Pub Date : 2024-01-18 DOI: 10.5483/bmbrep.2023-0210

Jong Hee Kim, Jihyeon Yu, Jin Young Kim, Yong Jin Park, Sangsu Bae, Kwon Kyoo Kang, Yu-Jin Jung

引用次数: 0

Applications of CRISPR technologies to the development of gene and cell therapy. 将 CRISPR 技术应用于基因和细胞疗法的开发。

IF 3.8 3区生物学

BMB Reports Pub Date : 2024-01-04 DOI: 10.5483/bmbrep.2023-0221

Chul-Sung Park, Omer Habib, Younsu Lee, J. Hur

{"title":"Applications of CRISPR technologies to the development of gene and cell therapy.","authors":"Chul-Sung Park, Omer Habib, Younsu Lee, J. Hur","doi":"10.5483/bmbrep.2023-0221","DOIUrl":"https://doi.org/10.5483/bmbrep.2023-0221","url":null,"abstract":"Advancements in gene and cell therapy have resulted in novel therapeutics for diseases previously considered incurable or challenging to treat. Among the various contributing technologies, genome editing stands out as one of the most crucial for the progress in gene and cell therapy. The discovery of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and the subsequent evolution of genetic engineering technology have markedly expanded the field of target-specific gene editing. Originally studied in the immune systems of bacteria and archaea, the CRISPR system has demonstrated wide applicability to effective genome editing of various biological systems including human cells. The development of CRISPR-based base editing has enabled directional cytosine-tothymine and adenine-to-guanine substitutions of select DNA bases at the target locus. Subsequent advances in prime editing further elevated the flexibility of the edit multiple consecutive bases to desired sequences. The recent CRISPR technologies also have been actively utilized for the development of in vivo and ex vivo gene and cell therapies. We anticipate that the medical applications of CRISPR will rapidly progress to provide unprecedented possibilities to develop novel therapeutics towards various diseases.","PeriodicalId":9010,"journal":{"name":"BMB Reports","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139385208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Loss of hepatic Sirt7 accelerates diethylnitrosamine (DEN)-induced formation of hepatocellular carcinoma by impairing DNA damage repair 肝脏 Sirt7 的缺失会损害 DNA 损伤修复，从而加速二乙基亚硝胺（DEN）诱导的肝细胞癌的形成

IF 3.8 3区生物学

BMB Reports Pub Date : 2024-01-04 DOI: 10.5483/BMBRep.2023-0187

Y. Kim, Baeki E Kang, Karim Gariani, Joanna Gariani, Junguee Lee, Hyun-Jin Kim, Chang-Woo Lee, Kristina Schoonjans, Johan Auwerx, Dongryeol Ryu

{"title":"Loss of hepatic Sirt7 accelerates diethylnitrosamine (DEN)-induced formation of hepatocellular carcinoma by impairing DNA damage repair","authors":"Y. Kim, Baeki E Kang, Karim Gariani, Joanna Gariani, Junguee Lee, Hyun-Jin Kim, Chang-Woo Lee, Kristina Schoonjans, Johan Auwerx, Dongryeol Ryu","doi":"10.5483/BMBRep.2023-0187","DOIUrl":"https://doi.org/10.5483/BMBRep.2023-0187","url":null,"abstract":"The mammalian sirtuin family (SIRT1–SIRT7) has shown diverse biological roles in the regulation and maintenance of genome stability under genotoxic stress. SIRT7, one of the least studied sirtuin, has been demonstrated to be a key factor for DNA damage response (DDR). However, conflicting results have proposed that Sirt7 is an oncogenic factor to promote transformation in cancer cells. To address this inconsistency, we investigated properties of SIRT7 in hepatocellular carcinoma (HCC) regulation under DNA damage and found that loss of hepatic Sirt7 accelerated HCC progression. Specifically, the number, size, and volume of hepatic tumor colonies in diethylnitrosamine (DEN) injected Sirt7-deficient liver were markedly enhanced. Further, levels of HCC progression markers and pro-inflammatory cytokines were significantly elevated in the absence of hepatic Sirt7, unlike those in the control. In chromatin, SIRT7 was stabilized and colocalized to damage site by inhibiting the induction of γH2AX under DNA damage. Together, our findings suggest that SIRT7 is a crucial factor for DNA damage repair and that hepatic loss-of-Sirt7 can promote genomic instability and accelerate HCC development, unlike early studies describing that Sirt7 is an oncogenic factor.","PeriodicalId":9010,"journal":{"name":"BMB Reports","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140514107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current status of genome editing technologies: special issue of BMB Reports in 2024. 基因组编辑技术的现状：2024 年 BMB 报告特刊。

IF 3.8 3区生物学

BMB Reports Pub Date : 2024-01-04 DOI: 10.5483/bmbrep.2023-0248

Ju-Chan Park, Sangsu Bae

引用次数: 0

Mitochondrial genome editing: strategies, challenges, and applications. 线粒体基因组编辑：策略、挑战和应用。

IF 3.8 3区生物学

BMB Reports Pub Date : 2024-01-04 DOI: 10.5483/bmbrep.2023-0224

Kayeong Lim

引用次数: 0

Mitochondrial genome editing: strategies, challenges, and applications. 线粒体基因组编辑：策略、挑战和应用。